The 27th of October, 2015, Rixos Borovoe hotel the first conference of Alliance of Experts in Biosimilars took place and Agreement of Intent signed on establishment of Association of Legal Entities “Association Alliance of Experts in Biosimilars”. T

During the first conference of Alliance of Experts in Biosimilars Agreement of Intent on establishment of Association of Legal Entities “Association Alliance of Experts in Biosimilars” signed Jiri Urbanec, Chimpharm CEO and Aigul Zhumanova, Director for EGIS Pharmaceutical Plant CJSC.

The Agreement covered the scope of Alliance of Experts in Biosimilars and joint efforts towards improvement of health of Kazakhstan people due to state-of-the-art medicinal products from biotechnologies (biosimilars) and development of scientific collaboration with international biosimilars companies.

Moreover, at the first conference of Alliance of Experts in Biosimilars use and authorization of biosimilars in EC and Kazakhstan were specifically discussed.

Prof. A.E. Guliayev, M.D., Leading Researcher, Center for Life Sciences, Nazarbayev University; Dr. Klaus Martin, Senior Director Business and Product Development, Polpharma Biologics; Prof. Pavel Grieb Head of Pharmacology and Expretimental Medicine Department, Institute of Experimental and Clinical Medicine n.a. M. Mossakowskiego, Academy of Sceince, Poland; Prof. R.L. Ivanova, State Medical University, Semei; Prof. I. Małysko, Head oft he 2nd Clinical Hospital for Nephrology at Medical University of Białystok , Poland and other Kazakhstan leading experts and clinicistst in biosimilar took part in the Conference.

It is great day. We are happy to sign the agreement on establishment of Alliance of Experts in Biosimilars with EGIS Company. This unique alliance will create conditions for all-round exchange with ideas, share of experience and knowledge in biosimilars. Biosimilars have completely changed the human vision of the medicine and open ways to treatment of lots of diseases. Biosimilars enable to provide many of patients with access to affordable medicinal products in treatment of serious diseases, improve life and longevity quality. In our production we apply advanced medicinal technologies and are willing to share our experience with Kazakhstan experts in biosimilars, says Jiri Urbanec, SANTO CEO.

Aigul Zhumanova, Director for EGIS Pharmaceutical Plant CJSC pointed out that establishment of Alliance of Experts in Biosimilars is an outstanding and big event for patients of Kazakhstan. The mission of Alliance is to widen access to state-of-the-art innovation therapy. Biosimilars give opportunity to obtain the most effective therapy in serious health problems. Health care is one of the main goals of EGIS Company and the Alliance establishment jointly with SANTO is the further proof of the companies’ social responsibility principle. Alliance of experts will build up understanding of biologic therapy and biosimilars role in treatment of serious diseases, raise most essential issues of their use, facilitate education of Kazakhstan experts in this category. The Alliance, with no doubts, will enable to resolve lots of vital issues in health care because we do match with principles of our partner. For EGIS and me personally, it is a great honor to participate in this project as the final goal of the Alliance is relief of patient’s distress.

Santo Member of Polpharma Group:

Santo Member of Polpharma Group is trade mark of Chimpharm JSC (KASE: CHFM). The Company has been developed, produced and supplied affordable high quality medicines to markets of Kazakhstan and Central Asia. Company’s facilities enable to produce annually 1bln tablets, capsules and granules, 300mln ampoules, 24mln vials of antibiotics and 4mln infusions. The company is Kazakhstan pharmaceutical market leader whose portfolio counts over 200 generic and innovation drugs for 12 pharmacotherapeutic groups in various therapy categories. Santo Member of Polpharma Group is a responsible employer for more than 1200 people in Shymkent and within all regions of Kazakhstan. The Company is an exporter for markets of five countries such as Russia, Kyrgyzstan, Tajikistan, Mongolia and Turkmenistan.

Additional information:
Tatyana Filipchik, PR-Manager
Santo
Al-Farabi Av., 15, Business center “Nurly Tau” 5B, 19th floor
050013, Almaty, Kazakhstan
Tel/fax: +7 (727) 312 18 33
e-mail: tatyana.filipchik@santo.kz
www.santo.kz

EGIS Company:

EGIS is one of the leading pharmaceutical companies in Central and Eastern Europe supplying it products to 67 countries including Kazakhstan. Its activities extend to the full cycle from development through production of finished products for sales and marketing. EGIS produces over 4.5bln tablets, 140mln boxes of medicines and 500-600 tons of active ingredients yearly. EGIS production system has been regularly certified on international standards GMP and FDA. In Kazakhstan EGIS is an active participator in scientific communities, research centers, master classes, education programs and patient adherence courses. Along with deep traditions the Company is directed to development, renovations and innovations. EGIS develops unique fixed dose combinations, innovation dosage forms etc. In 2013, the year of 100 anniversary, EGIS has launched to the market Infliximab the first biosimilar of mAb authorized by EMA and CIS countries, once again demonstrating its intention to provide patients with wider access to the most state-of-the-art and innovative pharmaceutical developments.

Additional information:
EGIS Pharmaceutical Plant, CJSC, RK Representative Office
050060, Alamty, Zharokov Str. 286
tel. 247-63-33, 247-63-34, fax. 247-61-41
www.egis.kz